Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029577 | 0.81 | LMNA (0.38) | LMNACTSAGAATSHRKMT2A | |
| SCHEMBL28620228 | 0.78 | NR4A2 (0.48) | NOTUMAKR1B1LMNAGAATSHR | |
| SCHEMBL627524 | 0.77 | KDM4E (0.53) | EIF4EAKR1B1LMNAGAA | |
| SCHEMBL866323 | 0.76 | EIF4E (0.43) | EIF4ECTSSCTSKKMT2A | |
| SCHEMBL6971887 | 0.72 | HDAC1 (0.56) | AKR1B1LMNAGAATSHRKMT2A | |
| SCHEMBL628001 | 0.72 | LMNA (0.46) | LMNAGAATSHRKMT2A | |
| SCHEMBL28494497 | 0.71 | NOTUM (0.49) | NOTUMCTSKTSHR | |
| SCHEMBL28787698 | 0.70 | FFAR1 (0.60) | NOTUMLMNAGAATSHR | |
| SCHEMBL1197790 | 0.70 | MPL (0.42) | NOTUMP2RX7CTSSCTSK | |
| SCHEMBL4415483 | 0.70 | LMNA (0.58) | LMNAGAATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | NOTUM 3362/4885EIF4E 2920/4885AKR1B1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.